Videos
Real-World Effectiveness of PARP Inhibitor Maintenance Therapy for Patients With Advanced Ovarian Cancer
06/21/2023
Debra Richardson, MD, Stephenson Cancer Center at University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, discusses results from a real-world analysis exploring the effectiveness of PARP inhibitor maintenance therapy in patients with advanced ovarian cancer specifically defined by biomarker status: BRCA1/2 and homologous recombination deficiency (HRD) signature.
Source:
Richardson DL, Quintanilha JCF, Graf R, et al. Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1/2 and HRD signature in real-world practice. Presented at 2023 ASCO Annual Meeting; June 2-6, 2023; Chicago, IL. Abstract 5583